| Added by | mollevi |
|---|---|
| Group name | EquipeCG |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, the Netherlands. US Oncology Research, Houston, Texas3Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada. Yale Cancer Center, Division of Oncology, Department of Medicine, New Haven, Connecticut. NSHI Dorozhnaya Clinical Hospital of OAO Russian Railways, Rostov-on-Don, Russia. Department of Uro-Oncology, Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warsaw, Poland. San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, Italy. Texas Oncology, Austin. University Hospital del Mar-IMIM, Barcelona, Spain10Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. US Oncology Research, Houston, Texas11Rocky Mountain Cancer Centers, Aurora, Colorado. Catalan Institute of Oncology, Department of Medical Oncology, Barcelona, Spain. Department of Clinical Oncology, The Christie NHS Foundation Trust and Institute of Cancer Sciences, University of Manchester, Manchester, England. Department of Urology, Rechts der Isar Medical Center, Technische Universitat Munchen, Munchen, Germany. State Institution of Healthcare " Regional Clinical Oncology Dispensary", Omsk, Russia. Centre Leon Berard, Department of Medical Oncology, Lyon, France. Department of Clinical Oncology, Royal Marsden Hospital, London, England. Medical Oncology Department, Groupe Hospitalier Universitaire Caremeau Place du Professeur Robert Debre, Nimes, France. Celgene Corporation, Summit, New Jersey. alt-title: JAMA oncology accession-num: 27560549 |
| Tags | _EndnoteXML import |
| Date Added | 2018/07/20 - 10:05:58 |
| Date Modified | 2018/07/20 - 10:05:58 |
| Parent item | Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study |
Institut de Recherche en Cancérologie de
